Published in final edited form as:

Trends Neurosci. 2011 May ; 34(5): 269–281. doi:10.1016/j.tins.2011.02.005.

Toll-like receptor Signaling in Neural Plasticity and Disease

Eitan Okun, Kathleen J. Griffioen, and Mark P. Mattson

Laboratory of Neurosciences, National Institute on Aging Intramural Research Program,
Biomedical Research Center, Baltimore, MD 21224.

Abstract

Toll-like receptors (TLRs) are a family of innate immune system receptors that respond to pathogen-derived and tissue damage-related ligands. TLR signaling in immune cells, glia and neurons may play roles in the pathogenesis of stroke, Alzheimer's disease and multiple sclerosis. Recent findings suggest that TLR signaling also influences multiple dynamic processes in the developing and adult central nervous system including neurogenesis, axonal growth and structural plasticity. In addition, TLRs are implicated in the regulation of behaviors including learning and memory, and anxiety. This review describes recently discovered and unexpected roles for TLRs in neuroplasticity, and the implications of these findings for future basic and translational research studies.

Toll-Like Receptors

Toll-like receptors (TLRs) are transmembrane pattern-recognition receptors (PRRs) that initiate signals in response to diverse pathogen-associated molecular patterns (PAMPs) (1). The first Toll protein was discovered in *Drosophila melanogaster*, where it controls dorso-ventral patterning (2). A mammalian homologue for Toll, TLR4, was later found to recognize bacterial lipopolysaccharide (LPS), a major cell wall component of gram-negative bacteria (3). Subsequently, many additional homologues have been identified across diverse species (for a comprehensive evolutionary overview, see (4)). Until recently, it was believed that while *Drosophila* Toll plays both immune and developmental roles, mammalian TLRs mediate immune responses of two kinds: 1) Orchestration of the immediate specific and global tissue response of the innate immune system to pathogens until the acquired immune response is fully functional. This orchestration is driven primarily by cytokine and chemokine production. 2) Facilitation of adaptive immunity by activating antigen-presenting cells such as macrophages and dendritic cells. Recent findings, however, suggest that mammalian TLRs also possess developmental roles during embryogenesis, as well as physiological and metabolic roles in adults. For example, TLR5-deficient mice exhibit hyperphagia and develop hallmark features of metabolic syndrome, including hyperlipidemia, hypertension, insulin resistance, and increased adiposity (5).

TLRs are expressed in a variety of mammalian immune system-related cell types including B cells (6), mast cells (7), natural killer cells (8), regulatory T cells (9), macrophages, monocytes, dendritic cells (10), neutrophils (11) and basophils (12), as well as non-immune

Corresponding author: Mark P. Mattson. mattsonm@grc.nia.nih.gov.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of interests

The authors declare no conflict of interests.

cells such as epithelial (12) and endothelial cells (13). TLRs are also present in the brain where, until recently, their expression was believed to be limited to microglia (14), astrocytes (15) and oligodendrocytes (16). However, we now know that neurons as well as neuronal progenitor cells also express TLRs (17).

TLRs rely on receptor dimerization to achieve specificity in agonist recognition. Although most TLRs form homodimers, certain TLRs such as TLR2 can also form heterodimers with TLR1 or 6 (1). In the context of PAMPs, the different TLRs respond to specific classes of pathogens. TLR4 predominantly recognizes LPS from gram-negative bacteria, while TLR2 dimerizes with TLR1 or TLR6 to recognize lipopeptides from gram-positive bacteria (1). TLR5 is expressed in the intestine where it senses bacterial flagellin protein (18,19). TLR11 generates an innate immune response upon sensing a parasite-specific surface motif consisting of an acidic loop on profilin from *T. gondii* (20,21). TLRs 3, 7, 8 and 9 are almost exclusively localized to intracellular membranes where they are ideally positioned for activation by nucleic acids of bacterial and viral origin (1). TLR3 is activated in response to viral double stranded RNA (dsRNA) (1). Human TLR8 and its murine orthologue TLR7 recognize viral ssRNA as well as various synthetic imidazoquinolines, compounds with a double cyclic organic backbone, which have different affinities toward TLR7 and TLR8 (22). TLR9 recognizes unmethylated CpG DNA found in bacteria as well as viral genomes (1).

In addition to the pathogen-derived ligands that activate the different TLRs, endogenous TLR ligands referred to as damage- (or danger-) associated molecular patterns (DAMPs) have been identified. Numerous endogenous ligands have been described and include: low molecular weight hyaluronic acid (LMW-HA), fibrinogen, fibronectin, β -defensins, heparin sulphate proteoglycans and heat-shock proteins (23,24). Importantly, the signaling outcomes seem to differ between PAMP and DAMP-induced TLR activation. This is probably due to the need to differentiate between pathogen-induced TLR activation that requires immune intervention and tissue damage-induced TLR activation that requires a balance between immune intervention and tissue damage repair (21,25,26). Endogenous TLR activation is one of the most exciting fields of TLR-related research today as it is realized that TLRs are not solely dedicated to eliciting pathogen-related immune responses, but also bear physiological as well as pathological roles unrelated to infection.

Following ligand binding, TLRs activate signaling components to initiate immune responses for host defense. The cytoplasmic region of TLRs shares a Toll/IL-1 receptor (TIR) domain, which mediates interactions between TLRs and TIR-domain containing adaptor proteins by either heterophilic or homophilic interaction of their TIR domains. The signaling pathways activated by TLRs are broadly classified into myeloid differentiation factor 88 (MyD88)-dependent and MyD88-independent pathways, with MyD88 the universal adapter protein recruited by all TLRs except for TLR3, which utilizes TIR-domain-containing adapter-inducing interferon- β (TRIF) to mediate signaling and TLR4 which utilizes both MyD88-dependent and TRIF-dependent signaling pathways (1).

TLRs are classically studied in relation to immunity, however recent evidence implicates TLRs as mediators of central nervous system (CNS) plasticity. While studies with pathogen-derived TLR ligands showed that TLR activation in the brain adversely affects cognition, recent findings suggest that TLRs regulate cognitive function in the absence of a pathogen-derived ligand. This review summarizes our current knowledge of TLRs in developmental and adult neuroplasticity, during physiological as well as neuropathological conditions.

TLR Signaling in CNS Cells

Activation of a given TLR engages different signaling pathways in different neural cell types. For example, TLR4 activation results in distinct signaling outcomes in astrocytes, microglia, neurons, neural progenitor cells (NPCs), and these pathways differ from TLR-induced signaling in dendritic cells (Fig. 1A). TLR4 activation in dendritic cells signals through a myeloid differentiation primary response gene 88 (MyD88)-dependent pathway to activate nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) and produce cytokines such as tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6) and IL-12. The MyD88-independent TRIF pathway is also activated resulting in nuclear translocation of Interferon regulatory factor (IRF)-3 and synthesis of Interferon β (IFN-β), which then activates its receptor coupled to Signal Transducer and Activator of Transcription 1 / 2 (STAT-1 / 2) and IRF-9 and a secondary wave of transcription of cytokines and chemokines such as Interferon gamma-induced protein 10 kDa (IP-10) and Glucocorticoid Attenuated Response Gene 16 (GARG16) (27). In astrocytes, however, TLR4 activates the MyD88- but not the TRIF-dependent pathway. In these cells, MyD88-mediated signaling leads to NFκB-induced transcription of TNF-α, vascular cell adhesion molecule 1 (VCAM-1) and IL-27, whereas other signaling mediators such as c-Jun N-terminal kinases (JNK) activate STAT-1 to transcribe IP-10 and suppressor of cytokine signaling proteins-1 (SOCS-1). Extracellular-signal-regulated kinases (ERK) is also activated by LPS in these cells independently of MyD88 (28). TLR4 activation in microglia resembles its activation of dendritic cells, with both MyD88- and TRIF-dependent signaling pathways active. These in turn induce NFκB activation that promotes transcription of cytokines such as TNF-α, IL-6 and IL-1β, and IRF-3 activation, resulting in IFN-β-mediated activation of STAT-1 and subsequently IRF-1 (29).

In contrast to other neural cells, the signaling outcomes of TLR4 activation in neurons are largely unknown. Recent findings indicate that in addition to TLR4, dorsal root ganglia (DRG) neurons express cluster of differentiation-14 (CD14), and myeloid differentiation protein (MD)-1, an MD-2 homologue, but lack the expression of Radioprotective 105 kDa (RP105) and have very low expression of MD-2 (30). RP105 is a TLR4 homologue that lacks the TIR-domain, and is thus unable to mediate signaling and inhibits TLR4. In immune cells, TLR4 binds MD-2, whereas RP105 binds MD-1. Neurons express an unusual assortment of TLR4 receptor complex components with MD-1 or MD-2 in addition to CD-14 (Fig. 1B). It is possible that this combination of proteins in the TLR4 receptor is responsible for the non-canonical signaling mediated by TLR4 in neurons. Neurons do not translocate NFκB to the nucleus, transcribe IFN-β or activate JNK (17), suggesting that neither of the known TLR4-induced signaling such as MyD88 and TRIF are activated in these cells as a result of TLR4 activation by LPS. It is known, however, that activation of NFκB in neurons influences their plasticity and survival. For example, activation of NFκB in hippocampal neurons induces the expression of manganese superoxide dismutase and protects neurons from being damaged and killed by oxidative and excitotoxic insults (31,32). NFκB has important roles in synaptic plasticity and learning and memory (33). Whether there are roles for NFκB in mediating effects of signaling from TLRs on neuronal plasticity is unknown and further research is required to answer this question.

TLRs in the Generation and Growth of Neurons

During embryonic development, extensive neurogenesis occurs in the sub-ventricular zone (SVZ, also referred to as the subependymal zone (SEZ) in the adult) of the lateral ventricles (34). Neurogenesis in this region slows significantly at early postnatal stages and continues modestly in the adult. NPCs derived from the SVZ tangentially migrate along the rostral migratory stream to the olfactory bulb, where they radially migrate and differentiate into

neurons of the granule and glomerular layers (35). In the adult mammalian brain, neurogenesis also occurs in the subgranular zone (SGZ) of the dentate gyrus (DG) in the hippocampus. Neurons arising from the SGZ differentiate and integrate into the DG as granule cells. The following sections review evidence that TLRs regulate NPC fate and the differentiation and growth of neurons in various stages of development and in the adult brain.

TLRs and neural progenitor cell proliferation

TLRs 2, 3 and 4 are expressed in NPCs, and recent evidence indicates that these receptors influence NPC proliferation (36-38). TLR4 inhibits NPC proliferation, as TLR4 deficiency increases NPC proliferation in the SGZ of the DG of adult mice, albeit without a corresponding increase in neuronal survival (38). TLR2 deficiency, however, does not alter proliferation of NPC in the adult hippocampus (38), or in the SVZ of the embryonic brain (37). Indeed, dual inhibition of TLR2 and TLR4 using neutralizing antibodies increases NPC self-renewal, an effect conferred by TLR4 (38). TLR3 deficiency also increases proliferation of embryonic NPCs in the SVZ during early but not late embryonic developmental stages (36). Interestingly, MyD88 deficiency also enhances NPC proliferation in the SGZ of the DG (38), suggesting that TLR signaling components are necessary to affect NPC proliferation, even in the absence of exogenous TLR ligands. While IL-1 signaling also relies on MyD88, it has not yet been determined whether MyD88-mediated effects on NPC proliferation involve IL-1 signaling, TLR signaling, or a combination of the two pathways. Similar to their effects on SVZ/SEZ and hippocampal NPCs, TLRs also alter proliferation of retinal progenitor cells (RPCs). During murine retinal development, multipotent RPCs give rise to neurons and Müller glia. TLR4 deficiency increases early postnatal RPC proliferation (39). Further, deficiency of downstream TIR adaptor proteins such as MyD88 and TRIF, two signaling mediators for TLR4, also enhances RPC proliferation.

TLR2 activation has differential effects on embryonic and adult NPCs. TLR2 activation depresses embryonic NPC proliferation (37), while in adult NPCs, TLR2 activation does not alter self-renewal ability (38,40). While TLR3 and 4 deficiencies enhance NPC proliferation, activation of these TLRs diminishes NPC self-renewal. TLR4 activation in adult NPCs activates both MyD88-dependent and -independent pathways (39) and ultimately results in inhibition of NPC proliferation (38). In addition, TLR4 activation by LPS inhibits the proliferative capacity of RPCs in neonates (39). TLR2 and TLR4 activation also stimulates TNF- α synthesis and release from adult NPCs, which may contribute to the inhibition of NPC proliferation (40). TLR3 activation reduces embryonic NPC proliferation to a greater extent than adult NPCs, correlating with the diminished control of TLR3 on NPC proliferation during the transition from early embryogenesis toward early postnatal ages (36). Figure 2 summarizes the effects of TLR deficiency (Fig. 2A) or activation (Fig. 2B) on NPC and RPC proliferation in embryos, neonates and the adult.

TLR4 activation in NPCs induces MyD88-dependent and -independent pathways, but little is known of the transcriptional targets that are downstream of these signaling mediators (38). NPC proliferation is altered by TLR or TIR adaptor protein deficiency (36,38) as well as TLR activation (37,38); however, the balance between TLR activation and inhibition and the resulting molecular mechanisms controlling NPC proliferation remain unclear. Another area that requires more investigation is the influence of TLR activation on the rostral migratory stream and neuronal distribution in the olfactory bulb. Differential rates of proliferation in the embryonic SVZ or adult SEZ may alter neuronal number in the adult olfactory bulb, leading to changes in olfaction. It will therefore be of interest to determine whether olfaction is affected by TLR signaling.

TLRs and NPC fate

TLRs are also implicated in the modulation of NPC differentiation. TLR2 deficiency alters the differentiation profile of NPCs, resulting in diminished numbers of neurons expressing the early neuronal markers doublecortin and β -III tubulin, and increased differentiation into cells expressing the astrocytic markers glial fibrillary acidic protein (GFAP) or S100 calcium binding protein B (S100 β) (38). TLR2 deficiency does not affect the fate of oligodendrocytes (41). Therefore, while TLR2 deficiency does not alter the proliferative capacity of NPCs, it suppresses neuronal differentiation, shifting NPCs toward an astrocytic fate. These effects are intrinsic to NPCs; wild type NPCs grown on TLR2-deficient mixed astrocyte-neuronal cultures retain a normal differentiation ratio of neurons to glia (38). In contrast, TLR4 deficiency enhances neuronal differentiation from NPCs but only marginally reduces differentiation into astrocytes (38). Dual inhibition of TLR2 and TLR4 using neutralizing antibodies increases neuronal differentiation, suggesting that the predominant effects on differentiation are mediated by TLR4 (38). Deficiency in MyD88, the common signaling mediator for TLR2 and TLR4, also enhances neuronal differentiation (38).

In contrast to TLR2 deficiency, TLR2 activation increases neuronal differentiation and simultaneously decreases astrocyte formation (38). However, others report no effect of TLR2 activation on adult NPC differentiation to neurons or glia (40). In contrast to TLR2, activation of TLR4 on adult NPCs using LPS reduces neuronal differentiation but has no effect on astrocyte differentiation (38). Similarly, TLR4 activation on RPCs inhibits neuronal differentiation without altering astrocyte differentiation (39). The impact of TLRs on NPC differentiation is summarized in Table 1. The involvement of TLRs and their activation by PAMPs in NPC differentiation raises interesting questions on the relevance of this phenomenon to physiological (sterile) conditions. The opposing effects on NPC differentiation conferred by TLR2 and TLR4 deficiency may not only be the result of endogenous activation, but also from developmental effects elicited by a deficiency of the receptor. This question could be answered by experiments in which the expression of TLR2 and 4 is suppressed or increased in a cell type-specific manner in the adult hippocampus.

TLRs and adult neurogenesis

Adult neurogenesis is a complex process that requires NPC proliferation, and the differentiation, migration and ultimately integration of neurons into existing networks. In mammals, neurogenesis from adult stem cells is responsible for the continuous maintenance and plasticity of only two major populations of neurons, interneurons of the olfactory bulb and granule neurons in the hippocampal DG. Several TLRs are implicated in the modulation of neurogenesis in the adult mammalian brain. TLR2-deficient mice exhibit significantly reduced neurogenesis, as indicated by expression of the early neuronal markers doublecortin and β III tubulin in bromodeoxyuridine (BrdU)-labeled cells (NPCs and their progeny) in the hippocampal SGZ. These mice have a higher proportion of cells in the hippocampal hilus expressing the astrocytic markers, but not the oligodendrocyte markers, indicating that TLR2 signaling promotes differentiation of NPCs into neurons at the expense of astrocytes (38).

The impact of TLR4 on neurogenesis *in vivo* is markedly different from TLR2. TLR4 deficiency increases cell proliferation, as measured by BrdU incorporation in the DG (38). However, these cells fail to survive and mature as neurons, indicating reduced neuronal survival in TLR4-deficient mice. On the other hand, the DG of TLR4-deficient mice contains a higher basal level of neurons and fewer glia compared to wild type mice. Similar effects are also observed in the SEZ (38). This could indicate that during embryonic development, TLR4-deficient NPCs proliferate and differentiate into neurons at a high rate, whereas in the adult, NPCs are highly proliferative but do not become fully mature neurons.

Interestingly, in contrast to the hippocampus, TLR4 deficiency in RPCs does not impair neuronal survival, and results in increased neuronal differentiation into rod photoreceptors and bipolar cells (39).

The role of TLR3 in adult neurogenesis has also been studied (42). While there is no alteration in total cell genesis in the DG of TLR3-deficient mice, these animals have a higher proportion of cells expressing the mature neuronal marker NeuN. Further, the hippocampal DG and CA1 of TLR3-deficient mice are enlarged, suggesting that TLR3 may be involved in regulating neurogenesis in the adult hippocampus (42).

An indication of the cumulative effects of TLRs on adult neurogenesis may be gained from MyD88-deficient mice. NPCs of MyD88-deficient mice exhibit higher proliferative capacity, and increased neuronal differentiation in the SGZ of the hippocampus (38). The latter result suggests a possible role for cytokines of the IL-1 family acting on IL-1 receptors (IL-1Rs) on neurogenesis, as such IL-1-related signaling would be expected to be impaired as the result of MyD88 deficiency.

TLRs and neurite outgrowth

The effects of TLRs in the CNS also extend to the development of neuronal circuits. TLR8 expression changes during the period of neuronal differentiation and axonogenesis. In mice, TLR8 is first detected at embryonic day 12 (E12), increases in later embryonic and neonatal stages, and decreases markedly after postnatal day 21 (P21) (43). Additionally, TLR8 exhibits a dynamic spatiotemporal expression. TLR8 is present in axonal tracts during embryogenesis and shifts to a diffuse expression in the neuronal soma postnatally, suggesting a role for TLR8 in nervous system development. Activation of TLR8 by the synthetic ligand R-848 significantly reduces the length of primary neurites. Further, R-848 results in neuronal death in a dose-dependent manner, independently of its effects on neurite outgrowth, while inhibition of TLR8 results in neurite elongation and reduced neuronal death (43,44). A negative effect on neuronal viability has only been demonstrated for TLR8; neuronal viability is not affected by activation of TLR3 (45), TLR4 (46) or TLR9 (47-49). However, when microglial cells are co-cultured with neurons, activation of TLRs 2 and 4 results in neuronal cell death (50). This provides a functional importance for the marked contrast between the signaling outcomes of TLR activation in neurons compared to microglia and astrocytes. Complementary studies are warranted to assess the effects of other TLRs and their activation on neuronal viability.

The developmental expression pattern of TLR3 contrasts with TLR8. TLR3 is strongly expressed during early embryogenesis, and decreases during the early postnatal period where it maintains a low expression (36). Similar to TLR8, TLR3 activation by either the synthetic ligand PolyI:C, or the DAMP mRNA inhibits neurite growth from embryonic day 9 (E9) chick DRG neurons as well as E14 mouse embryonic brains. This effect, however, is not accompanied by increased neuronal cell death (45). TLR3-induced neurite growth cone collapse is rapid and independent of transcriptional regulation or NF κ B activation. Further, TLR3 is strongly expressed by sensory neurons. Intrathecal PolyI:C administration to mouse pups at postnatal day 4 (P4) diminishes sensorimotor function and decreases dorsal root ganglion neurofilament expression, which is important for nerve growth and regeneration (45). Notably, neurite outgrowth is only affected by TLR3 activation; TLR3-deficient neurons do not exhibit augmented neurite outgrowth. The diverse roles of TLR8 and TLR3 in neurite development and neuronal cell death are summarized in Figure 3A, and the temporal expression of the different TLRs discussed above is illustrated in Figure 3B. Similar to TLR4 activation, the signaling pathways induced by TLR3 and TLR8 activation by PAMPs in neurons are devoid of NF κ B, AP1, JNK or ERK activation, again stressing the striking difference between TLR activation in neurons compared to other cells in the

CNS. The signaling pathway(s) underlying the effects of TLR activation on neurite growth in neurons therefore remains an open question.

TLRs and Cognition

The growing body of evidence of the involvement of TLRs in neurogenesis, neurite outgrowth and neuron survival suggests that TLRs might also impact cognitive processes in health, injury and/or disease. It was recently shown that TLR3 has broad effects on the cognitive performance of mice in hippocampal-dependent and -independent behavioral tasks (42). While TLR3-deficient mice have intact spatial reference memory, memory extinction is slower than control mice. TLR3 deficiency also confers superior performance in spatial working memory. Conversely, activation of TLR3 by intracerebroventricular (ICV) infusion of PolyI:C diminishes working memory performance. These results should be interpreted with caution, however, because PolyI:C may also activate the intracellular helicases retinoid-inducible gene I (RIG-I) and Melanoma Differentiation-Associated Gene 5 (MDA-5).

Similar to memory retention in a water maze task, contextual fear memory is also enhanced in TLR3-deficient mice (41). Interestingly, anxiety appears to be increased in TLR3-deficient mice, and amygdala-dependent performance is blunted (42). The effects of TLR3 on cognition are summarized in Figure 3C. These effects emphasize the role of TLR3 under normal conditions, devoid of infection or tissue damage, which excludes receptor activation through PAMPs or DAMPs. Endogenous ligands for TLR3 include mRNA (51), as well as stathmin (52). However, the availability in vivo of such ligands to activate TLR3 under normal conditions has not yet been established. A mechanism by which mRNA can activate TLR3 has not been demonstrated, and stathmin expression is strongly enhanced under neuroinflammatory conditions suggesting a role for stathmin in TLR3 activation in pathological states. Further work is required to elucidate roles for endogenous TLR3 ligands in modifying cognitive processes. It is also important to determine whether TLR3 signaling influences cognition via developmental effects or direct effects on synaptic plasticity. The possible roles of TLRs 2, 4 and 8 on cognition remain to be determined, but seem likely given the evidence that these receptors profoundly alter neural NPC proliferation and differentiation (TLR2 and TLR4) and neurite outgrowth (TLR8). Cognition has been assessed in transgenic mice overexpressing or deficient for other TIR-domain containing receptors, such as IL-1R (53). However, it remains to be elucidated whether there is a link between signaling from IL-1R and other TIR-domain containing receptors such as the TLR family in the context of cognition.

In addition to the studies of TLR-deficient mice described above, the effects of specific TLR agonists on cognitive performance have also been investigated. These studies must be interpreted with caution, however, due to variations in concentration and timing of treatments as well as the effects of state-dependent changes. State-dependent changes are particularly relevant for cognitive tests, as they can abrogate learning and memory by impairing the motivation to perform a task, a process that is not hippocampal dependent. For example, a high dose of LPS (0.25 µg/hr for 28 days) impairs spatial learning, associated with neuronal death (54), while a very high acute dose of LPS (20 µg) causes similar impairments in spatial learning associated with synaptic loss or damage (55). At these doses, the effects of LPS on cognition are due to neuropathology, rather than reversible inhibition of plasticity. In another study, acute ICV injection of low doses of LPS (1-100 ng) induced depressive-like behavior as well as sickness, which include decreased appetite, weight loss, and reduced interest in the physical and social environment, which are mediated by TNF-α (56). Thus, the fact that low doses of LPS induce sickness behavior precludes any

conclusions on the specific effects of TLR4 activation in the brain on hippocampus-dependent cognitive behavior.

TLR9 activation also exerts effects on spatial learning and memory; ICV infusion of CpG DNA (1 µg/day) over 4 weeks results in increased latency to reach the platform in a water-maze task (57). While this dose did not adversely affect motor function, significant brain pathology was observed including microglial activation, acute axonal damage surrounding the ventricles, ependymal disruption and reactive astrogliosis within the hippocampus. This implies that the memory impairments are due to neurotoxicity rather than due to a pharmacological effect of activation of TLR9 on pathways known to alter synaptic transmission or plasticity-related molecular pathways. In this regard, while it is widely accepted that neuroinflammation causes cognitive impairment, we would like to emphasize the possible contribution of TLR-mediated signaling to non-neuroinflammation mediated pathways that affect cognitive behavior. Our current knowledge on the effects of brain-specific activation of TLRs 3, 9 and 4 is summarized in Figure 3D.

TLRs in CNS Infection

The well-established ligands for TLRs in the context of infection are molecules on or liberated from bacteria, viruses and other invading pathogens. The responses of cells to such pathogen-derived ligands have been most extensively studied in immune cells, particularly dendritic cells and macrophages (58,59). In the CNS, microglia express several different TLRs that, when activated by PAMPs, induce the production of pro-inflammatory cytokines including IL-6 and TNF α (60,61). Microglia can be activated during systemic infections without the blood-brain barrier (BBB) being compromised suggesting that PAMPs can either cross the BBB and/or activate macrophages and microglia in circumventricular organs. Alternatively, macrophages and/or circulating cytokines can pass the BBB and intercept invading pathogens in the brain and/or activated microglial cells. There is evidence that localized activation of TLR4 in BBB-associated macrophages/microglia can trigger a 'wave' of microglial activation that spreads within the brain parenchyma; this transcellular wave of innate immune cell activation is believed to be propagated by TNF- α (62). TLR activation can and does result in different outcomes in different types of CNS cells. When TLR3 is activated in human astrocytes, a comprehensive neuroprotective response was suggested to occur, in contrast to the pro-inflammatory reaction of microglial cells (63), however, the majority of the studies, support the view that TLR3 activation in human astrocytes contribute to a pro-inflammatory phenotype of astrocytes (64).

This emphasizes the importance of studying cell-specific responses to TLR activation in the context of the cellular network in the CNS. A range of infectious conditions have been associated with activation of one or more TLRs in macrophages/microglia in the CNS (61), and several of these TLRs are involved in limiting and clearing bacterial and viral infections of the CNS (Table 2). An understanding of the mechanisms by which the innate immune system in the brain responds to pathogens has benefited greatly from animal models of meningitis and encephalitis. TLR2 and TLR4 play key roles in the response of cells in the CNS to pneumococcal meningitis (65). The immune response of mice lacking both TLR2 and 4 to intracisternal pneumococcal infection is more severely impaired than that of mice lacking either TLR2 or TLR4 alone. Mice lacking TLR2, 4 and 9 have similar susceptibility as mice lacking TLRs 2 and 4 to pneumococcal meningitis. Importantly, When TLR2/4 double-deficient mice received bone marrow transplants from wild type mice, a cerebral immune response occurred and the pneumococcal infection was attenuated (65). This result emphasizes that in the case of cerebral meningitis, TLR2 and 4 expression on circulating immune cells is critical for a successful immune response to infection in the brain.

Encephalitis caused by herpes simplex virus (HSV) infection results in an inflammatory response in the CNS, and TLR2 and TLR9 act synergistically to stimulate innate antiviral activities, thereby protecting against HSV infection in the brain (66). This again implies that synergism rather than redundancy exists in the TLR family of receptors in pathogen response in general, and in the brain in particular. HSV-1 is a double-stranded DNA virus with double-stranded RNA (dsRNA) intermediates. Molecular genetic studies suggest that mutations in TLR3 may render some humans vulnerable to HSV encephalitis (67). Human TLR3 also appears to be largely redundant for antiviral immunity, as TLR3-deficient patients have infections with numerous viruses without developing severe disease. Nevertheless, human TLR3 is essential for primary immunity to HSV-1 in the CNS, at least in some circumstances. This is an example of an individual TLR playing a nonredundant role in host defense due to its ability to recognize dsRNA.

Two additional infectious agents to which TLRs respond are West Nile virus (WNV) and human immunodeficiency virus (HIV). Studies of TLR3-deficient mice have resulted in seemingly conflicting conclusions regarding the role of TLR3 in WNV pathogenesis. An initial report provided evidence that TLR3 plays a pivotal role in the entrance of WNV into the brain (68), whereas a more recent report indicated that TLR3 protects the brain against WNV (69). This discrepancy may result from distinct routes of inoculation, passage history of the virus and/or the viral dose (69). MyD88 restricts WNV by inhibiting replication in subsets of cells and preventing immune cell migration into the CNS. Mice deficient for MyD88 show increased lethality after WNV infection and elevated viral burden in the brain (70). Sterile alpha- and armadillo-motif-containing protein (SARM) is the only known inhibitory mammalian TIR-domain containing adaptor protein. WNV replication is also increased specifically in the brainstem of SARM-deficient mice, and is associated with enhanced mortality (71). SARM deficiency is also linked to reduced levels of TNF- α , decreased microglia activation, and increased neuronal death in the brainstem after WNV infection. Thus, SARM functions to restrict viral infection and neuronal injury in a brain region-specific manner, possibly by modulating the activation of resident CNS inflammatory cells (71). It is logical that MyD88 deficiency results in enhanced mortality following WNV infection, as MyD88 is the main adaptor protein involved in TLR-related response to WNV. However, that deficiency in SARM results in a similar effect is of interest because: 1) SARM is highly expressed in the brain (71), and 2) SARM acts to inhibit TLR3- and TLR4-mediated responses (72). The immunological phenotypes of MyD88 and SARM provide additional evidence that immunological responses in the brain require tight regulation.

The adverse effects of aberrant TLR activation caused by systemic infections might also alter brain development in utero. Indeed, TLR2 activation using the synthetic bacterial lipopeptides Palmitoyl-cysteinyl-seryl-(lysyl₄) (Pam₃CSK₄) and Follistatin-like 1 (FSL1), or low-molecular weight hyaluronic acid (LMW-HA) (a TLR2 and TLR4 DAMP (73)) inhibits the proliferation of NPCs in the brains of developing mouse embryos resulting in cortical dysgenesis (37). Related to this, a vast literature shows causative links between maternal exposure to TLR ligands and brain structure as well as behavioral deficits in offspring, deficits suggested by some to mimic maternal infections in humans that have been proposed (though not proven) to contribute to some cases of schizophrenia in the offspring. For a comprehensive review, see (74).

The Toll of Brain Injury

Two general types of injury to the CNS that are very common and associated with morbidity and mortality are ischemic injury (stroke) and traumatic injury to the brain or spinal cord. By inducing the production of pro-inflammatory cytokines and excitotoxins, activation of TLR4 and TLR2 in microglia likely contributes to the neuronal damage that occurs after a

stroke (75-78). TLR2 and TLR4 signaling in neurons may also contribute to their demise after a stroke because levels of TLRs 2 and 4 are increased in cerebral cortical neurons in response to ischemia/reperfusion injury, and the amount of brain damage and neurological deficits caused by a stroke are reduced in mice deficient in TLR2 or TLR4 (17). However, in contrast to the typical MyD88 – NF κ B signaling pathway that induces cytokine production in microglia, the cell death-promoting actions of TLR2 and 4 in ischemic neurons are mediated by JNK and the transcription factor AP-1 (17). TLR3 and TLR9, in contrast, do not alter ischemic stroke outcome (79). A short ischemic event (ischemic preconditioning) results in a subsequent resistance to severe ischemia. TLR4-deficient mice exhibit reduced ischemic preconditioning-induced neuroprotection compared to wild-type mice (75). TLR4 deficiency maintains levels of TNF- α , inducible nitric oxide synthase (iNOS), cyclooxygenase-2 and NF κ B below wild-type levels. These data demonstrate that TLR4 signaling is involved in brain tolerance to ischemic damage (80). While the endogenous TLR ligands that may activate TLRs during a stroke are unknown, recent findings suggest a role for the DAMP HMGB1 in TLR4 activation (81).

Very little information is available concerning the roles of TLRs in traumatic injury to the CNS. Axotomy-induced degeneration of RGCs was reduced in TLR4-deficient mice and this neuroprotection was associated with decreased activation of JNK and p38 kinases, and reduced iNOS levels (78). In a stab-wound model of cortical brain injury the activation of microglia and astrocytes was reduced in mice lacking TLR2 (82). Additionally, the expression of the heme oxygenase-1 (*HO-1*) gene, a glia-expressed wound-responsive gene, was reduced after stab-wound injury in TLR2 knockout mice. This implies that TLR2 contributes to glial cell activation and HO-1 production associated with traumatic brain injury. Information is lacking regarding the roles of other TLRs in traumatic CNS injury.

Inflammation of the lumbar spinal cord following traumatic injury, or peripheral nerve injury, is associated with pain (83). Acute activation of TLR4 by intrathecal LPS administration in rodents is associated with hyperalgesia and pain. LPS is a potent inducer of nociception / orphanin FQ (N/OFQ), an opioid-related peptide that plays a key role in pain physiology, and blockade of either TLR4 or MD-1, a member of the TLR4 complex, prevents N/OFQ expression (46). It was recently shown that CNS TLR4 activation increases p38 phosphorylation and increases extracellular ATP production. ATP then activates the purinergic receptor P2X7 that further increases p38 phosphorylation and causes secretion of mature IL-1 β (83). IL-1 β can modulate neuronal mechanisms of chronic pain in the dorsal horn via the MyD88 pathway. Thus, by activating TLR4 using LPS, two signaling cascades that utilize the adaptor protein MyD88 facilitate nociception, stressing the importance of the TLR/TIR adaptor protein family in this aspect of neuronal plasticity. In this respect, it is important to bear in mind that LPS is an exogenous, rather than endogenous, TLR4 ligand. The inflammatory process following LPS activation may be supplemented with endogenous activation once inflammation occurs in the tissue; however, it is possible that initial activation of TLR4 using an endogenous ligand will induce different outcomes. Not all TLRs are implicated in pain, however, as TLR7 is not necessary to elicit mechanical, thermal, inflammatory and neuropathic pain in mice (84). However, TLR7 expressed on DRG neurons does mediate itch sensation (pruritus) primarily by non-histamine pruritogens (84). TLR7 ligands likely elicit itch via a direct action on sensory neurons, however non-neuronal cells could also be involved in this process.

Emerging Roles for TLRs in Neurodegenerative and Demyelinating Diseases

Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder with a devastating effect on the patients and their caregivers. AD involves local inflammatory

cellular and molecular alterations associated with the characteristic pathological changes, amyloid deposits and tau tangles. Amyloid β -peptide ($A\beta$) is generated as a proteolytic product of the amyloid precursor protein (APP). $A\beta$ self-aggregates and accumulates on the surface of neurons and in large 'plaques', while another protein, termed tau, accumulates within neurons in brain regions critical for learning and memory, including the hippocampus and frontal cortex (85). The possible involvement of one or more TLRs in AD is suggested from multiple studies described below.

TLR2 deficiency exacerbates memory impairments in a mouse model of AD and this adverse effect of TLR2 deficiency can be rescued by TLR2-expressing bone marrow-derived cells, possibly by stimulating macrophage/microglia-mediated clearance of $A\beta$ from the brain (86). Thus, TLR2 may act as an endogenous receptor for the clearance of toxic $A\beta$ by bone-marrow-derived immune cells because activation of TLR2 markedly enhances formylpeptide receptor-like 2 (mFPR2)-mediated uptake of $A\beta_{42}$ by microglia (87). Ligands that activate TLR2, TLR4 or TLR9 increased the uptake of $A\beta$ by a microglial cell line in culture (88) and TLRs 2 and 4 may be required for microglial activation by $A\beta$ plaques in vivo (89). Exposure of microglia to the TLR9 ligand CpG DNA protects neurons against $A\beta$ toxicity in cell culture, reduces $A\beta$ aggregation and ameliorates $A\beta$ -induced memory impairment in mice (90). Additionally, treatment of APP mutant transgenic mice with CpG DNA resulted in reduced $A\beta$ in the cerebral cortex and cerebral blood vessels, and ameliorated spatial learning deficits associated with $A\beta$ pathology (91).

A comparison of cytokine levels in the brains of AD mice that express or lack TLR4 revealed a pivotal role for TLR4 in disease-associated production of $TNF\alpha$, IL1- β , IL-10 and IL-17 (92). TLR4 deficiency inhibits the activation of microglia and monocytes by $A\beta$ resulting in lower IL-6, $TNF\alpha$ and nitric oxide production (93). Neurons from TLR4 mutant mice exhibited reduced vulnerability to $A\beta_{42}$ -induced cell death (94). Finally, a genetic association study suggested that a polymorphism (Asp299Gly) in TLR4 may reduce the risk of AD independently of a polymorphism in apolipoprotein E (95), suggesting that genes involved in TLR signaling may influence susceptibility to AD. Collectively, the available data suggest that multiple TLRs are activated in brain cells in AD; activation of some TLRs in microglia (TLRs 2, 4 and 9) may either counteract the disease process by enhancing $A\beta$ clearance, whereas activation of TLRs in neurons (TLR4) may increase their vulnerability to oxidative stress and $A\beta$ toxicity.

The most common demyelinating disease is multiple sclerosis (MS), a disorder characterized by damage to myelinated axons in the brain and spinal cord. TLR2 expression in oligodendrocytes is elevated in MS lesions, and TLR2-specific agonists (but not TLR4 or 5 agonists) inhibit the maturation of cultured oligodendrocyte progenitor cells (OPCs) (41). Interestingly, OPCs produce enzymes that degrade extracellular hyaluronan to fragments that activate TLR2 and so inhibit remyelination. Figure 4 illustrates the proposed involvement of TLR2 in the inhibition of remyelination by oligodendrocytes in MS. In experimental autoimmune encephalitis (EAE), a mouse model of MS, the infiltration of neutrophils and lymphocytes occurs coincidentally with axonal damage, and is associated with the accumulation of vesicular TLR8 inside the axons (96). Evidence for activation of TLR8 persisted even after the disappearance of leukocytes from the spinal cord suggesting a potential role for this TLR in progression of the MS disease process.

It was recently reported that TLR3 and stathmin, a putative endogenous ligand for TLR3, are co-localized in chronic active MS lesions in patients (52), suggesting a role for endogenous activation of TLR3 in this disease. More studies are needed, however, in order to show that stathmin can exacerbate disease progression in a TLR3-dependent manner.

MyD88 is necessary for activation of peripheral dendritic cells and Th17 cells in the induction of EAE in animal models of MS (97,98). On the other hand, early life exposure to the TLR4 agonist, LPS, suppresses EAE by promoting tolerogenic dendritic cells and regulatory T cells, whereas TLR4 deficiency exacerbates disease progression (97,99). In contrast to the effect of TLR4 activation, *Streptococcus pneumoniae* infection exacerbates EAE via a TLR2-mediated mechanism (100). TLR2 may function synergistically with other TLRs that are activated by *S. pneumoniae*.

TLR9 also plays a complex role in EAE; it decreases disease severity in myelin oligodendrocyte glycoprotein (MOG)-induced EAE, but exacerbates the disease induced by MOG35-55. Interestingly, a study in which MyD88 or TLR9 (but not TLR2) deficiencies were restricted to host radiation-resistant cells suggests that endogenous TLR ligands modulate MS disease pathogenesis (98). The discrepancy between these studies on the role of TLR9 may be due to technical differences in inducing the disease in mice and warrants further investigation. 15alpha-hydroxicholestene (15-HC) is an oxidized derivative of cholesterol, which is found in high levels in the serum of MS patients as well as mice induced with EAE. While deficiency for TLR2 has no effect on the severity of MOG-induced EAE, exogenously administered 15-HC was found to mediate its damage in a TLR2 dependent manner (101). While this suggests a possible therapeutic approach for MS, the fact that TLR2 deficient mice are not protected against EAE suggests that the endogenous levels of 15-HC in EAE-induced mice are not sufficient to efficiently exacerbate the disease in a TLR2-dependent manner. It is clear, however, that signaling through MyD88 is critical in disease development and therefore identifies TLRs as targets for the development of therapeutic interventions in MS.

Conclusion and Future Directions

The concept that the same protein acquires multiple roles during evolution is exemplified in TLRs, which initially emerged as a family of innate immune receptors, and are now being recognized as modulators of CNS plasticity. TLRs influence NPC proliferation, differentiation, neurite outgrowth and behavioral plasticity. However, while evidence from mice deficient in TLRs strongly implicates these receptors in neuroplasticity, the distinction between developmental and functional effects of life-long deficiency of a TLR, as well as specific roles for TLRs in neuroplasticity following infection and injury remains unclear (Box 2). Future studies focused on the role of TLRs in discrete regions of the CNS in health and disease will provide valuable insight into the expanding role of TLRs in the function and plasticity of the nervous system.

Little is known regarding if and how TLR signaling interacts with other signaling pathways involved in developmental and adult neuroplasticity. Glutamate is the major excitatory neurotransmitter in the CNS and activation of both AMPA and NMDA subtypes of glutamate receptors is essential for synaptic plasticity/learning and memory. Neurons lacking either TLR2 or TLR4 exhibit increased resistance to the adverse effects of energy deprivation, an experimental model in which activation of glutamate receptors plays a role in the cell death process (17). Interestingly, TLR3 deficiency affects levels of activated cAMP response element-binding (CREB), a transcription factor that plays important roles in learning and memory and that is known to be activated in response to glutamate receptor stimulation (42). Another signaling pathway that one or more TLRs may interact with is the phosphoinositide 3-kinase (PI3 kinase) / Akt pathway that is activated by neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and insulin-like growth factors (IGFs). Both BDNF and IGF-1 promote neurogenesis, enhance synaptic plasticity and protect neurons against a range of metabolic, oxidative and excitotoxic stressors (102). Because several TLRs (2 and 4, in particular) increase the vulnerability of neurons to

oxidative and metabolic stresses, it might be expected that BDNF and IGF-1 signaling would counteract the adverse effects of TLR2 and 4 signaling, although this remains to be determined.

Another largely unexplored issue concerns how, at the levels of signal transduction and gene expression, TLRs affect the proliferation, differentiation, outgrowth, plasticity and survival of neurons. The emerging findings described above suggest the existence of a complex TLR signaling network that influences neural plasticity by both direct effects on NPC and neurons, and indirect glia-mediated processes. Further studies of the signaling outcomes of TLR activation by endogenous and extrinsic ligands in neurons and glial cells will provide novel insights into the roles of these ancient receptors in the generation, plasticity and pathology of the nervous system.

Box 1: The relevance of endogenous ligands to physiological conditions

The subject of endogenous ligands has leapt in the past several years from being regarded as 'endotoxin contamination' to the forefront of research in the TLR fields. There is no doubt that under various pathological conditions from cancer, stroke to physical wounds, endogenous epitopes are exposed and detected by TLRs. These observations cannot, however, explain how TLRs confer effects in the absence of a PAMP or DAMP, as occurs in physiological conditions. Two signaling events are plausible under physiological conditions: 1) There are ligands that are not considered 'damage associated molecular patterns', but rather 'physiologically occurring molecular patterns' that contribute to constitutive TLR activation; 2) Constitutive TLR activation is not mediated by ligands, but rather by unknown co-receptors that together mediate a non-cannonical signaling pathway. The two possible explanations must be tested in order to determine which pathway is predominant under physiological conditions by TLRs.

Box 2: Unanswered Questions

1. What are the endogenous ligands that activate TLRs under physiological conditions, in the absence of tissue damage? Are self-mRNA and stathmin relevant for non-inflammatory conditions?
2. Does TLR3 signaling affect cognition by altering the development of neuronal circuits and/or by more acute effects on synaptic plasticity? Do TLRs other than TLR3 have an impact on cognition?
3. What signaling pathways are initiated by TLRs to mediate neurological effects, and do they differ among various CNS cell lineages?
4. Do IL-1R and TLR signaling cooperate in shaping CNS plasticity?
5. Does TLR signaling affect cognition during aging?
6. Do TLRs contribute to cognitive impairment that occurs as the result of CNS infections?
7. Do one or more TLR signaling pathways modify signaling cascades activated by neurotransmitters and neurotrophic factors?
8. What are the transcription factors and gene targets that mediate effects of TLR activation on neurogenesis, neurite outgrowth, neuronal plasticity and behavior?
9. Can specific, CNS-penetrant TLR antagonists and agonists be identified and developed as therapeutic interventions for CNS injury and disease?

Acknowledgments

The authors' work was supported by the Intramural Research Program of the National Institute on Aging.

References

1. Kawai T, Akira S. TLR signaling. *Seminars in immunology*. 2007; 19(1):24–32. [PubMed: 17275323]
2. Valanne S, Wang JH, Ramet M. The Drosophila toll signaling pathway. *J Immunol*. 2011; 186(2): 649–656. [PubMed: 21209287]
3. Okun E, et al. Toll-like receptors in neurodegeneration. *Brain Res Rev*. 2009; 59(2):278–292. [PubMed: 18822314]
4. Leulier F, Lemaitre B. Toll-like receptors--taking an evolutionary approach. *Nature reviews*. 2008; 9(3):165–178.
5. Vijay-Kumar M, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. *Science*. 2010; 328(5975):228–231. [PubMed: 20203013]
6. Gerondakis S, Grumont RJ, Banerjee A. Regulating B-cell activation and survival in response to TLR signals. *Immunol Cell Biol*. 2007; 85(6):471–475. [PubMed: 17637697]
7. Iwamura C, Nakayama T. Toll-like receptors in the respiratory system: their roles in inflammation. *Curr Allergy Asthma Rep*. 2008; 8(1):7–13. [PubMed: 18377768]
8. Eriksson M, et al. TLRs mediate IFN-gamma production by human uterine NK cells in endometrium. *J Immunol*. 2006; 176(10):6219–6224. [PubMed: 16670332]
9. Suttmuller R, Garritsen A, Adema GJ. Regulatory T cells and toll-like receptors: regulating the regulators. *Ann Rheum Dis*. 2007; 66(Suppl 3):iii91–95. [PubMed: 17934105]
10. Kaisho T, Akira S. Toll-like receptor function and signaling. *J Allergy Clin Immunol*. 2006; 117(5):979–987. quiz 988. [PubMed: 16675322]
11. Sabroe I, Whyte MK. Toll-like receptor (TLR)-based networks regulate neutrophilic inflammation in respiratory disease. *Biochem Soc Trans*. 2007; 35(Pt 6):1492–1495. [PubMed: 18031251]
12. Yoshimoto T, Nakanishi K. Roles of IL-18 in basophils and mast cells. *Allergol Int*. 2006; 55(2): 105–113. [PubMed: 17075246]
13. Gibson FC 3rd, Ukai T, Genco CA. Engagement of specific innate immune signaling pathways during *Porphyromonas gingivalis* induced chronic inflammation and atherosclerosis. *Front Biosci*. 2008; 13:2041–2059. [PubMed: 17981690]
14. Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. *J Immunol*. 2004; 173(6):3916–3924. [PubMed: 15356140]
15. Bowman CC, Rasley A, Tranguch SL, Marriott I. Cultured astrocytes express toll-like receptors for bacterial products. *Glia*. 2003; 43(3):281–291. [PubMed: 12898707]
16. Aravalli RN, Peterson PK, Lokensgard JR. Toll-like receptors in defense and damage of the central nervous system. *J Neuroimmune Pharmacol*. 2007; 2(4):297–312. [PubMed: 18040848]
17. Tang SC, et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. *Proceedings of the National Academy of Sciences of the United States of America*. 2007; 104(34):13798–13803. [PubMed: 17693552]
18. Uematsu S, et al. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. *Nature immunology*. 2008; 9(7):769–776. [PubMed: 18516037]
19. Smith KD, et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. *Nature immunology*. 2003; 4(12):1247–1253. [PubMed: 14625549]
20. Kucera K, et al. Structure-based analysis of *Toxoplasma gondii* profilin: a parasite-specific motif is required for recognition by Toll-like receptor 11. *J Mol Biol*. 2010; 403(4):616–629. [PubMed: 20851125]
21. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. *Seminars in immunology*. 2007; 19(1):3–10. [PubMed: 17275324]

22. Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. *Oncogene*. 2008; 27(2):190–199. [PubMed: 18176600]
23. Pandey S, Agrawal DK. Immunobiology of Toll-like receptors: emerging trends. *Immunol Cell Biol*. 2006; 84(4):333–341. [PubMed: 16834572]
24. Lehnardt S, et al. A vicious cycle involving release of heat shock protein 60 from injured cells and activation of toll-like receptor 4 mediates neurodegeneration in the CNS. *J Neurosci*. 2008; 28(10):2320–2331. [PubMed: 18322079]
25. Liu Y, Chen GY, Zheng P. CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns. *Trends Immunol*. 2009; 30(12):557–561. [PubMed: 19786366]
26. Shimada M, et al. Hyaluronan fragments generated by sperm-secreted hyaluronidase stimulate cytokine/chemokine production via the TLR2 and TLR4 pathway in cumulus cells of ovulated COCs, which may enhance fertilization. *Development*. 2008; 135(11):2001–2011. [PubMed: 18434414]
27. Hemmi H, Akira S. TLR signalling and the function of dendritic cells. *Chem Immunol Allergy*. 2005; 86:120–135. [PubMed: 15976491]
28. Gorina R, Font-Nieves M, Marquez-Kisinousky L, Santalucia T, Planas AM. Astrocyte TLR4 activation induces a proinflammatory environment through the interplay between MyD88-dependent NFkappaB signaling, MAPK, and Jak1/Stat1 pathways. *Glia*. 2011; 59(2):242–255. [PubMed: 21125645]
29. Jung DY, et al. TLR4, but not TLR2, signals autoregulatory apoptosis of cultured microglia: a critical role of IFN-beta as a decision maker. *J Immunol*. 2005; 174(10):6467–6476. [PubMed: 15879150]
30. Divanovic S, et al. Inhibition of TLR-4/MD-2 signaling by RP105/MD-1. *J Endotoxin Res*. 2005; 11(6):363–368. [PubMed: 16303092]
31. Mattson MP, Maudsley S, Martin B. A neural signaling triumvirate that influences ageing and age-related disease: insulin/IGF-1, BDNF and serotonin. *Ageing research reviews*. 2004; 3(4):445–464. [PubMed: 15541711]
32. Mattson MP, Barger SW, Begley JG, Mark RJ. Calcium, free radicals, and excitotoxic neuronal death in primary cell culture. *Methods in cell biology*. 1995; 46:187–216. [PubMed: 7541884]
33. Mattson MP, Goodman Y, Luo H, Fu W, Furukawa K. Activation of NF-kappaB protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration. *Journal of neuroscience research*. 1997; 49(6):681–697. [PubMed: 9335256]
34. Lathia JD, Rao MS, Mattson MP, Ffrench-Constant C. The microenvironment of the embryonic neural stem cell: lessons from adult niches? *Dev Dyn*. 2007; 236(12):3267–3282. [PubMed: 17937403]
35. Duan X, Kang E, Liu CY, Ming GL, Song H. Development of neural stem cell in the adult brain. *Current opinion in neurobiology*. 2008; 18(1):108–115. [PubMed: 18514504]
36. Lathia JD, et al. Toll-like receptor 3 is a negative regulator of embryonic neural progenitor cell proliferation. *J Neurosci*. 2008; 28(51):13978–13984. [PubMed: 19091986]
37. Okun E, et al. TLR2 activation inhibits embryonic neural progenitor cell proliferation. *Journal of neurochemistry*. 2010; 114(2):462–474. [PubMed: 20456021]
38. Rolls A, et al. Toll-like receptors modulate adult hippocampal neurogenesis. *Nature cell biology*. 2007; 9(9):1081–1088.
39. Shechter R, et al. Toll-like receptor 4 restricts retinal progenitor cell proliferation. *The Journal of cell biology*. 2008; 183(3):393–400. [PubMed: 18981228]
40. Covacu R, et al. TLR activation induces TNF-alpha production from adult neural stem/progenitor cells. *J Immunol*. 2009; 182(11):6889–6895. [PubMed: 19454685]
41. Sloane JA, et al. Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107(25):11555–11560. [PubMed: 20534434]
42. Okun E, et al. Toll-like receptor 3 inhibits memory retention and constrains adult hippocampal neurogenesis. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107(35):15625–15630. [PubMed: 20713712]

43. Ma Y, et al. Toll-like receptor 8 functions as a negative regulator of neurite outgrowth and inducer of neuronal apoptosis. *The Journal of cell biology*. 2006; 175(2):209–215. [PubMed: 17060494]
44. Ma Y, Haynes RL, Sidman RL, Vartanian T. TLR8: an innate immune receptor in brain, neurons and axons. *Cell cycle (Georgetown, Tex)*. 2007; 6(23):2859–2868.
45. Cameron JS, et al. Toll-like receptor 3 is a potent negative regulator of axonal growth in mammals. *J Neurosci*. 2007; 27(47):13033–13041. [PubMed: 18032677]
46. Acosta C, Davies A. Bacterial lipopolysaccharide regulates nociceptin expression in sensory neurons. *Journal of neuroscience research*. 2008; 86(5):1077–1086. [PubMed: 18027846]
47. Iliev AI, Stringaris AK, Nau R, Neumann H. Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9). *FASEB J*. 2004; 18(2):412–414. [PubMed: 14688201]
48. Okun E, Lathia JD, Mattson MP. Adhesion- and migration-related side effects of phosphothioated CpG oligodeoxynucleotides. *Cell adhesion & migration*. 2009; 3(3):272–274. [PubMed: 19458479]
49. Okun E, Mattson MP. Phosphothioated oligodeoxynucleotides induce nonspecific effects on neuronal cell adhesion in a growth substrate-dependent manner. *Journal of neuroscience research*. 2009; 87(8):1947–1952. [PubMed: 19156868]
50. Trudler D, Farfara D, Frenkel D. Toll-like receptors expression and signaling in glia cells in neuro-amyloidogenic diseases: towards future therapeutic application. *Mediators Inflamm*. 2010 doi: 10.1155/2010/497987.
51. Kariko K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. *The Journal of biological chemistry*. 2004; 279(13):12542–12550. [PubMed: 14729660]
52. Bsibsi M, et al. The microtubule regulator stathmin is an endogenous protein agonist for TLR3. *J Immunol*. 2010; 184(12):6929–6937. [PubMed: 20483774]
53. Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. *Brain, behavior, and immunity*. 2011; 25(2):181–213.
54. Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. *Nat Rev Immunol*. 2006; 6(5):404–416. [PubMed: 16639431]
55. Tanaka S, et al. Lipopolysaccharide-induced microglial activation induces learning and memory deficits without neuronal cell death in rats. *Journal of neuroscience research*. 2006; 83(4):557–566. [PubMed: 16429444]
56. Palin K, et al. The type 1 TNF receptor and its associated adapter protein, FAN, are required for TNF α -induced sickness behavior. *Psychopharmacology*. 2009; 201(4):549–556. [PubMed: 18825372]
57. Tauber SC, et al. Stimulation of Toll-like receptor 9 by chronic intraventricular unmethylated cytosine-guanine DNA infusion causes neuroinflammation and impaired spatial memory. *Journal of neuropathology and experimental neurology*. 2009; 68(10):1116–1124. [PubMed: 19918123]
58. Bauer S, Muller T, Hamm S. Pattern recognition by Toll-like receptors. *Advances in experimental medicine and biology*. 2009; 653:15–34. [PubMed: 19799109]
59. Schaffler A, Scholmerich J. Innate immunity and adipose tissue biology. *Trends in immunology*. 2010; 31(6):228–235. [PubMed: 20434953]
60. Lehnardt S. Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. *Glia*. 2010; 58(3):253–263. [PubMed: 19705460]
61. Suh HS, Brosnan CF, Lee SC. Toll-like receptors in CNS viral infections. *Current topics in microbiology and immunology*. 2009; 336:63–81. [PubMed: 19688328]
62. Baker BJ, Park KW, Qin H, Ma X, Benveniste EN. IL-27 inhibits OSM-mediated TNF- α and iNOS gene expression in microglia. *Glia*. 2010; 58(9):1082–1093. [PubMed: 20468050]
63. Bsibsi M, et al. Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators. *Glia*. 2006; 53(7):688–695. [PubMed: 16482523]
64. Kim H, et al. Double-stranded RNA mediates interferon regulatory factor 3 activation and interleukin-6 production by engaging Toll-like receptor 3 in human brain astrocytes. *Immunology*. 2008; 124(4):480–488. [PubMed: 18248388]

65. Klein M, et al. Innate immunity to pneumococcal infection of the central nervous system depends on toll-like receptor (TLR) 2 and TLR4. *J Infect Dis.* 2008; 198(7):1028–1036. [PubMed: 18700834]
66. Sorensen LN, et al. TLR2 and TLR9 synergistically control herpes simplex virus infection in the brain. *J Immunol.* 2008; 181(12):8604–8612. [PubMed: 19050280]
67. Zhang SY, et al. TLR3 deficiency in patients with herpes simplex encephalitis. *Science.* 2007; 317(5844):1522–1527. [PubMed: 17872438]
68. Wang T, et al. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. *Nat Med.* 2004; 10(12):1366–1373. [PubMed: 15558055]
69. Daffis S, Samuel MA, Suthar MS, Gale M Jr, Diamond MS. Toll-like receptor 3 has a protective role against West Nile virus infection. *J Virol.* 2008; 82(21):10349–10358. [PubMed: 18715906]
70. Szretter KJ, et al. The innate immune adaptor molecule MyD88 restricts West Nile virus replication and spread in neurons of the central nervous system. *J Virol.* 2010; 84(23):12125–12138. [PubMed: 20881045]
71. Szretter KJ, et al. The immune adaptor molecule SARM modulates tumor necrosis factor alpha production and microglia activation in the brainstem and restricts West Nile Virus pathogenesis. *J Virol.* 2009; 83(18):9329–9338. [PubMed: 19587044]
72. O'Neill LA. DisSARMing Toll-like receptor signaling. *Nature immunology.* 2006; 7(10):1023–1025. [PubMed: 16985498]
73. Erridge C. Endogenous ligands of TLR2 and TLR4: agonists or assistants? *J Leukoc Biol.* 2010; 87(6):989–999. [PubMed: 20179153]
74. Boksa P. Effects of prenatal infection on brain development and behavior: a review of findings from animal models. *Brain, behavior, and immunity.* 2010; 24(6):881–897.
75. Caso JR, et al. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. *Circulation.* 2007; 115(12):1599–1608. [PubMed: 17372179]
76. Hua F, et al. Activation of Toll-like receptor 4 signaling contributes to hippocampal neuronal death following global cerebral ischemia/reperfusion. *J Neuroimmunol.* 2007; 190(1-2):101–111. [PubMed: 17884182]
77. Lehnardt S, et al. Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. *J Neuroimmunol.* 2007; 190(1-2):28–33. [PubMed: 17854911]
78. Kilic U, Kilic E, Matter CM, Bassetti CL, Hermann DM. TLR-4 deficiency protects against focal cerebral ischemia and axotomy-induced neurodegeneration. *Neurobiol Dis.* 2008; 31(1):33–40. [PubMed: 18486483]
79. Hyakkoku K, et al. Toll-like receptor 4 (TLR4), but not TLR3 or TLR9, knockout mice have neuroprotective effects against focal cerebral ischemia. *Neuroscience.* 2010; 171(1):258–267. [PubMed: 20804821]
80. Pradillo JM, et al. Toll-like receptor 4 is involved in neuroprotection afforded by ischemic preconditioning. *Journal of neurochemistry.* 2009; 109(1):287–294. [PubMed: 19200341]
81. Yang QW, et al. HMBG1 mediates ischemia-reperfusion injury by TRIF-adaptor independent Toll-like receptor 4 signaling. *J Cereb Blood Flow Metab.* 2011; 31(2):593–605. [PubMed: 20700129]
82. Park C, et al. Toll-like receptor 2 contributes to glial cell activation and heme oxygenase-1 expression in traumatic brain injury. *Neurosci Lett.* 2008; 431(2):123–128. [PubMed: 18164130]
83. Clark AK, et al. P2X7-dependent release of interleukin-1beta and nociception in the spinal cord following lipopolysaccharide. *J Neurosci.* 2010; 30(2):573–582. [PubMed: 20071520]
84. Liu T, Xu ZZ, Park CK, Berta T, Ji RR. Toll-like receptor 7 mediates pruritus. *Nat Neurosci.* 2010; 13(12):1460–1462. [PubMed: 21037581]
85. Mattson MP. Pathways towards and away from Alzheimer's disease. *Nature.* 2004; 430(7000):631–639. [PubMed: 15295589]
86. Richard KL, Filali M, Prefontaine P, Rivest S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. *J Neurosci.* 2008; 28(22):5784–5793. [PubMed: 18509040]

87. Chen K, et al. Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide. *The Journal of biological chemistry*. 2006; 281(6):3651–3659. [PubMed: 16339765]
88. Tahara K, et al. Role of toll-like receptor signalling in Abeta uptake and clearance. *Brain*. 2006; 129(Pt 11):3006–3019. [PubMed: 16984903]
89. Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE. CD14 and toll-like receptors 2 and 4 are required for fibrillar A β -stimulated microglial activation. *J Neurosci*. 2009; 29(38):11982–11992. [PubMed: 19776284]
90. Doi Y, et al. Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid β neurotoxicity in in vitro and in vivo models of Alzheimer's disease. *Am J Pathol*. 2009; 175(5):2121–2132. [PubMed: 19834064]
91. Scholtzova H, et al. Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. *J Neurosci*. 2009; 29(6):1846–1854. [PubMed: 19211891]
92. Jin JJ, Kim HD, Maxwell JA, Li L, Fukuchi K. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. *Journal of neuroinflammation*. 2008; 5:23. [PubMed: 18510752]
93. Walter S, et al. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. *Cell Physiol Biochem*. 2007; 20(6):947–956. [PubMed: 17982277]
94. Tang SC, et al. Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. *Exp Neurol*. 2008; 213(1):114–121. [PubMed: 18586243]
95. Minoretti P, et al. Effect of the functional toll-like receptor 4 Asp299Gly polymorphism on susceptibility to late-onset Alzheimer's disease. *Neurosci Lett*. 2006; 391(3):147–149. [PubMed: 16157451]
96. Soulika AM, et al. Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis. *J Neurosci*. 2009; 29(47):14965–14979. [PubMed: 19940192]
97. Marta M, Andersson A, Isaksson M, Kampe O, Lobell A. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. *Eur J Immunol*. 2008; 38(2):565–575. [PubMed: 18203139]
98. Prinz M, et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. *J Clin Invest*. 2006; 116(2):456–464. [PubMed: 16440059]
99. Ellestad KK, et al. Early life exposure to lipopolysaccharide suppresses experimental autoimmune encephalomyelitis by promoting tolerogenic dendritic cells and regulatory T cells. *J Immunol*. 2009; 183(1):298–309. [PubMed: 19542441]
100. Herrmann I, et al. Streptococcus pneumoniae Infection aggravates experimental autoimmune encephalomyelitis via Toll-like receptor 2. *Infect Immun*. 2006; 74(8):4841–4848. [PubMed: 16861672]
101. Farez MF, et al. Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. *Nature immunology*. 2009; 10(9):958–964. [PubMed: 19684606]
102. Meyer U, Feldon J, Yee BK. A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. *Schizophrenia bulletin*. 2009; 35(5):959–972. [PubMed: 18408229]
103. Salaria S, et al. Toll-like receptor pathway gene expression is associated with human immunodeficiency virus-associated neurodegeneration. *J Neurovirol*. 2007; 13(6):496–503. [PubMed: 18097881]
104. Marta M, Meier UC, Lobell A. Regulation of autoimmune encephalomyelitis by toll-like receptors. *Autoimmun Rev*. 2009; 8(6):506–509. [PubMed: 19211042]
105. Fu X, et al. Central administration of lipopolysaccharide induces depressive-like behavior in vivo and activates brain indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures. *Journal of neuroinflammation*. 2010; 7:43. [PubMed: 20678226]

Figure 1. TLR4 signaling in dendritic cells compared to neural cells

(A) In dendritic cells, LPS induced TLR4 signaling occurs through both MyD88-dependent and -independent pathways. A MyD88-dependent pathway leads to rapid activation of NFκB and Mitogen-activated protein (MAP) kinases and production of inflammatory cytokines. A MyD88-independent pathway induces slow activation of NFκB and MAP kinases as well as IRF-3. The activation of IRF-3 induces production of IFN-β. Secreted IFN-β stimulates IFN-β receptor which leads to activation of STAT1 and STAT2, resulting in induction of IFN-inducible genes such as IP-10 and GARG-16 in dendritic cells (27). In astrocytes, LPS induces early recruitment of MyD88 and subsequent activation of MyD88-dependent pathway leading to NFκB activation. NFκB is activated after degradation of IκB-α, p65 phosphorylation and nuclear translocation of NFκB subunits (p65 and p50), followed by p38-dependent transcriptional activity of the NFκB complex and induction of target genes including TNF-α, IL-27, IL-15, Matrix metalloproteinase (MMP)-9 and vascular cell adhesion protein 1 (VCAM-1). Induction of TRIF-dependent IFN-β is not detected in astrocytes, but a MyD88-independent pathway induces delayed, MAPK, JNK and p38-mediated, tyrosine phosphorylation of STAT1, and activation of downstream genes IP-10 and SOCS-1. Phosphorylation of ERK1/2 is involved in Egr-1, IL-15, and MMP-9 induction. STAT1 can exert a negative control on the expression of certain genes, such as MMP-9. Microglial signaling initiated by TLR4 consists of at least two pathways, MyD88-mediated NFκB activation and TRIF-mediated IRF-3 activation. Activated IRF-3 induces IFN-β expression, which via IFN-β receptors initiates STAT1 signaling that activates IRF-1. TLR4 on NPCs exposed to LPS mediates signaling through both the MyD88-dependent pathway that results in NFκB activation, as well as through TRIF, which activates IRF-3. Neurons treated with LPS show no activation of NFκB, TRIF or JNK pathways (37,38).

(B) The TLR4 signaling complex in immune cells and neurons. In human and rodent immune cells, TLR4 dimers bind to the adaptor proteins CD14 and MD-2. An additional complex comprised of RP105 and MD-1 serves as an inhibitor of TLR4. In rodent neurons, TLR4 dimers bind CD14 and either MD-1 or MD-2 (30,46).

Figure 2. TLRs and NPC proliferation

(A) (Left panel) Deficiency of TLR3 but not TLR2 increases proliferation of SVZ-derived embryonic NPCs (36,37). (Middle panel) Deficiency of TLR4, MyD88 or TRIF increases proliferation of RPCs in neonates (39). (Right panel) Deficiency of TLR4, MyD88 or TRIF but not TLR2 or TLR3 increases proliferation of DG-derived adult NPCs (36,38). (B) (Left panel) Activation of TLR2 by Pam3CSK4, TLR3 by PolyI:C or TLR4 by LPS inhibits proliferation of SVZ-derived embryonic NPCs (36-38). (Middle panel) Activation of TLR4 using LPS inhibits proliferation of RPCs in neonates (39). (Right panel) Activation of TLR4 by LPS, and to a lesser extent activation of TLR3 with PolyI:C (but not TLR2 using Pam3CSK4), inhibits DG-derived adult NPC proliferation (36-38,40,42). Activation of TLR2 and TLR4 with the above ligands also induces the release of TNF- α in these cells. This figure describes work performed in mice.

Figure 3. TLRs in CNS development, plasticity and cognition

(A) The impact of TLRs on neurite outgrowth and neuronal survival. TLR8 deficiency increases neurite outgrowth and inhibits cell death. TLR8 activation using R-848 inhibits neurite outgrowth and reduces neuronal survival. TLR3 activation using PolyI:C inhibits neurite outgrowth (43-45). (B) Developmental CNS expression patterns for select TLRs in mice. TLR2 expression increases from early embryonic stages into adulthood. TLR3 is expressed during early embryonic stages and gradually declines into adulthood where it maintains low expression, mainly in neurons. TLR4 expression increases from early embryonic stages into adulthood. TLR8 expression increases from early embryonic stages until P21. Subsequently, TLR8 expression diminishes during adulthood, and is maintained at a low level (36,37,43,44). (C) TLR3 deficiency has pleiotrophic effects on behavior in mice. Spatial working memory and memory extinction, but not reference memory, is improved. Contextual memory of fear, as well as fear memory extinction is also enhanced. In addition, amygdala-dependent cued fear memory and anxiety responses are impaired. Short-term recognition memory is enhanced (42). (D) ICV infusion of the TLR4 ligand LPS results in sickness coupled with depressive-like behavior (54-56,105). ICV infusion of the TLR3 ligand PolyI:C results in spatial working memory impairment (42). ICV infusion of the TLR9 ligand CpG DNA results in spatial reference memory impairments (57). This figure represents work performed in mice.

Figure 4. The role of TLR2 in oligodendrocyte differentiation and myelination in MS
 Oligodendrocytes found in human MS lesions express elevated levels of TLR2. OPCs secrete hyaluronidase that cleaves HMW-HA into LMW-HA, which in turn, inhibits murine OPC maturation and myelination in a TLR2-MyD88 dependent manner (41). HMW-HA: high molecular weight hyaluronan; LMW-HA: low-molecular weight hyaluronan..

Table 1

TLRs and neuronal differentiation

Neural cells	Influence on NPC differentiation						
	Genetic manipulations			Pathological modulation			
	Δ TLR4	Δ TLR2	Δ MyD88	LPS TL4	Pam3CSK4 TLR2	Flagellin TLR5	
<u>NPC-derived cells</u>							
Neurons (β III T^+ , DCX $^+$)	$\uparrow$ (38)	$\downarrow$ (38)	$\uparrow$ (38)	$\downarrow$ (38)	$\uparrow$ (38) / — (40)	N/A	
Astrocytes (S100 β^+ , GFAP $^+$)	$\downarrow$ (38)	$\uparrow$ (38)	$\downarrow$ (38)	$\uparrow$ (38)	$\downarrow$ (38) / — (40)	N/A	
Oligodendrocytes (MBP $^+$, NG2 $^+$)	— (38)	— (38)	N/A (38)	— (38, 41)	— (38) / $\downarrow$ (40, 41)	— (41)	
<u>RPC-derived cells</u>							
Neurons (β III T^+ , DCX $^+$)				$\downarrow$ (39)			
Astrocytes (S100 β^+ , GFAP $^+$)				— (39)			

Table 2

Involvement of TLRs in CNS infection, injury and disease.

Condition	TLR/TIR	Role and influence on disease outcome	Ref.
Infections			
Meningitis (bacterial)	TLR2 + 4	clearance of infectious agents	(65)
	TLR9	no effect	(65)
Meningitis (viral)	TLR2 + 9	stimulates innate anti-viral activities	(66)
West Nile virus	TLR3	mediates WNV entry into the brain causing lethal encephalitis	(68)
	TLR3	Protective role against WNV infection	(69)
	MyD88	restricts viral infection	(70)
	SARM	restrict viral replication	(71)
Herpes simplex	TLR2 + 9	reduction in viral load in the brain	(66)
	TLR3	vital for natural immunity to HSV-1 in the CNS	(67)
HIV AIDS	TLR4	induces glial reactivity and inflammation	(103)
Injury			
Ischemic stroke	TLR2 + 4	enhancement of neuronal death and functional	(17)
		Deficits	(79)
	TLR3 + 9	no effect	(79)
	HMGB1 (TLR4)	exacerbates ischemic damage	(81)
Ischemic Preconditioning	TLR4	mediates Ischemic preconditioning-induced neuroprotection	(80)
Traumatic injury	TLR2, 4	exacerbates neuronal injury	(78)
			(82)
Disease			
Alzheimer's disease	TLR2	TLR2 acts as an endogenous receptor for the clearance of toxic Aβ by bone-marrow-derived immune cells	(86)
	PGN (TLR2)	increased uptake of Aβ by microglial cell line	(88)
	LPS (TLR4)	in vitro	
	CpG ODN (TLR9)		
		TLR9	protects against Aβ toxicity, reduces Aβ
		toxicity, reduces Aβ aggregation, ameliorates Aβ induced memory impairments	(91)
	TLR2, 4	clearance (phagocytosis) of Aβ by microglia In-vivo	(89)
	TLR4	reduces microglial activation by Aβ	(93)
		increases vulnerability of neurons to Aβ	(94)
		ASP299GLY polymorphism reduces the risk of AD in humans	(95)
		increases TNF-α, IL-1β, IL-10 and IL-17 in the brains of an AD mouse model	(92)
Multiple sclerosis	S. Pneumoniae (TLR2)	exacerbates EAE by a TLR2-mediated mechanism	(100)
	Hyaluronic Acid (TLR2)	adverse effect on OPCs; blocks remyelination	(41)
	TLR2	TLR2 deficiency does not affect EAE progression	(98)
	15-HC (TLR2)	Exacerbates MOG(35-55) induced EAE	(101)
	TLR4	Exacerbates EAE induced disease outcome	(97)
	LPS (TLR4)	Early life exposure to lipopolysaccharide suppresses EAE	(99)
	TLR9	ameliorates EAE induced by MOG(35-55)	(104)

Condition	TLR/TIR	Role and influence on disease outcome	Ref.
	TLR9	exacerbates EAE severity induced by MOG	(98)
	MyD88	delays onset of the disease	(98)
		Protects from EAE	(97)